The Effect of Delivery Systems on the Induction of T Helper 1 Cell Response to an ESAT6-Like Protein Rv3619c and Identification of Its Immunodominant Peptides

Overview

Journal Med Princ Pract

Publisher Karger

Specialties General Medicine
Medical Education

Date 2022 May 18

PMID 35584661

Authors

Hussain A Safar

Abu Salim Mustafa

Hanady A Amoudy

Ahmed El-Hashim

Affiliations

Soon will be listed here.

Abstract

Objective: This study determined the effects of chemical adjuvants, incomplete Freund's adjuvant (IFA) and aluminum hydroxide (Alum), mycobacteria, and a DNA plasmid as delivery systems on the induction of protective Th1 (interferon-gamma (IFN-γ)) and nonprotective Th2 (IL-5) and Treg (IL-10) cytokine responses to Rv3619c and its peptides. Rv3619c is an immunodominant Mycobacterium tuberculosis-specific antigen and belongs to the early-secreted antigenic target of 6 kDa-family of proteins. Delivery systems are needed to deliver such antigens in animal models and induce protective immune responses.

Methods: The rv3619c gene was amplified from the genomic DNA of M. tuberculosis and cloned into appropriate vectors for expression in Escherichia coli, Mycobacterium smegmatis, and eukaryotic cells. Spleen cells from mice immunized with rv3619c using different delivery systems were stimulated in vitro with synthetic peptides (P1 to P6) of Rv3619c, and secreted cytokines were estimated by ELISA.

Results: The recombinant M. smegmatis and DNA plasmid induced the secretion of the protective cytokine IFN-γ in response to peptide-pool of Rv3619c and all the individual peptides, whereas rv3619c/IFA induced the secretion of IFN-γ in response to the peptide pool, and the peptides P5 and P6. However, the secretions of the nonprotective cytokines IL-5 and IL-10 were induced to none of the peptides with the delivery systems used.

Conclusion: Rv3619c is a major antigen of M. tuberculosis with multiple immunogenic epitopes; however, immune responses to individual epitopes can vary based on delivery systems used.

Citing Articles

Tuberculosis vaccines and therapeutic drug: challenges and future directions.

An Y, Ni R, Zhuang L, Yang L, Ye Z, Li L Mol Biomed. 2025; 6(1):4.

PMID: 39841361 PMC: 11754781. DOI: 10.1186/s43556-024-00243-6.

Optimizing antigen selection for the development of tuberculosis vaccines.

Yang Y, Chen Y, Xia T Cell Insight. 2024; 3(3):100163.

PMID: 38572176 PMC: 10987857. DOI: 10.1016/j.cellin.2024.100163.

Chemical and Biological Characterization of Mycobacterium Tuberculosis-Specific ESAT6-Like Proteins and their Potentials in the Prevention of Tuberculosis and Asthma.

Mustafa A Med Princ Pract. 2023; .

PMID: 37703836 PMC: 10659698. DOI: 10.1159/000534002.

References

Gong W, Liang Y, Wu X . The current status, challenges, and future developments of new tuberculosis vaccines. Hum Vaccin Immunother. 2018; 14(7):1697-1716. PMC: 6067889. DOI: 10.1080/21645515.2018.1458806. View

Ansari M, Zubair S, Mahmood A, Gupta P, Khan A, Gupta U . RD antigen based nanovaccine imparts long term protection by inducing memory response against experimental murine tuberculosis. PLoS One. 2011; 6(8):e22889. PMC: 3154911. DOI: 10.1371/journal.pone.0022889. View

Brandt L, Oettinger T, Holm A, Andersen A, Andersen P . Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J Immunol. 1996; 157(8):3527-33. View

Junqueira-Kipnis A, de Oliveira F, Trentini M, Tiwari S, Chen B, Resende D . Prime-boost with Mycobacterium smegmatis recombinant vaccine improves protection in mice infected with Mycobacterium tuberculosis. PLoS One. 2013; 8(11):e78639. PMC: 3826754. DOI: 10.1371/journal.pone.0078639. View

Wang P, Wang L, Zhang W, Bai Y, Kang J, Hao Y . Immunotherapeutic efficacy of recombinant Mycobacterium smegmatis expressing Ag85B-ESAT6 fusion protein against persistent tuberculosis infection in mice. Hum Vaccin Immunother. 2013; 10(1):150-8. PMC: 4181032. DOI: 10.4161/hv.26171. View

Mustafa A . Immunological Characterization of Proteins Expressed by Genes Located in -Specific Genomic Regions Encoding the ESAT6-like Proteins. Vaccines (Basel). 2021; 9(1). PMC: 7825740. DOI: 10.3390/vaccines9010027. View

Szulc-Kielbik I, Brzostek A, Gatkowska J, Kielbik M, Klink M . Determination of in vitro and in vivo immune response to recombinant cholesterol oxidase from Mycobacterium tuberculosis. Immunol Lett. 2020; 228:103-111. DOI: 10.1016/j.imlet.2020.11.002. View

Brandt L, Elhay M, Rosenkrands I, Lindblad E, Andersen P . ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun. 2000; 68(2):791-5. PMC: 97206. DOI: 10.1128/IAI.68.2.791-795.2000. View

de Oliveira F, Trentini M, Junqueira-Kipnis A, Kipnis A . The mc2-CMX vaccine induces an enhanced immune response against Mycobacterium tuberculosis compared to Bacillus Calmette-Guérin but with similar lung inflammatory effects. Mem Inst Oswaldo Cruz. 2016; 111(4):223-31. PMC: 4830111. DOI: 10.1590/0074-02760150411. View

10.

Banchereau J, Schuler-Thurner B, Palucka A, Schuler G . Dendritic cells as vectors for therapy. Cell. 2001; 106(3):271-4. DOI: 10.1016/s0092-8674(01)00448-2. View

11.

Park I, Shim T . Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis treatment. Korean J Intern Med. 2016; 32(2):302-308. PMC: 5339471. DOI: 10.3904/kjim.2016.199. View

12.

Alving C, Matyas G, Torres O, Jalah R, Beck Z . Adjuvants for vaccines to drugs of abuse and addiction. Vaccine. 2014; 32(42):5382-9. PMC: 4403865. DOI: 10.1016/j.vaccine.2014.07.085. View

13.

Xu J, Xu W, Chen X, Zhao D, Wang Y . Recombinant DNA vaccine of the early secreted antigen ESAT-6 by Mycobacterium tuberculosis and Flt3 ligand enhanced the cell-mediated immunity in mice. Vaccine. 2008; 26(35):4519-25. DOI: 10.1016/j.vaccine.2008.06.044. View

14.

OHagan D, De Gregorio E . The path to a successful vaccine adjuvant--'the long and winding road'. Drug Discov Today. 2009; 14(11-12):541-51. DOI: 10.1016/j.drudis.2009.02.009. View

15.

Safar H, El-Hashim A, Amoudy H, Mustafa A . -Specific Antigen Rv3619c Effectively Alleviates Allergic Asthma in Mice. Front Pharmacol. 2020; 11:532199. PMC: 7546857. DOI: 10.3389/fphar.2020.532199. View

16.

Orr M, Fox C, Baldwin S, Sivananthan S, Lucas E, Lin S . Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J Control Release. 2013; 172(1):190-200. PMC: 3871206. DOI: 10.1016/j.jconrel.2013.07.030. View

17.

Mustafa A, Amoudy H, Wiker H, Abal A, Ravn P, Oftung F . Comparison of antigen-specific T-cell responses of tuberculosis patients using complex or single antigens of Mycobacterium tuberculosis. Scand J Immunol. 1998; 48(5):535-43. DOI: 10.1046/j.1365-3083.1998.00419.x. View

18.

Martin E, Kamath A, Briscoe H, Britton W . The combination of plasmid interleukin-12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette-Guèrin) in protecting against systemic Mycobacterim avium infection. Immunology. 2003; 109(2):308-14. PMC: 1782959. DOI: 10.1046/j.1365-2567.2003.01660.x. View

19.

Lu Y, Kang J, Ning H, Wang L, Xu Y, Xue Y . Immunological characteristics of Mycobacterium tuberculosis subunit vaccines immunized through different routes. Microb Pathog. 2018; 125:84-92. DOI: 10.1016/j.micpath.2018.09.009. View

20.

Tkachuk A, Gushchin V, Potapov V, Demidenko A, Lunin V, Gintsburg A . Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models. PLoS One. 2017; 12(4):e0176784. PMC: 5409163. DOI: 10.1371/journal.pone.0176784. View